Clinical characteristics and therapeutic behavior of breast cancer patients using mistletoe therapy consulting a clinic offering integrative oncology: a registry data analysis

Table 2 Type of care and start of MT or COM by hormone and Her2 status

		Total	HR+/ HER2+	HR+/ HER2-	HR+/ HER2?	HR-/ HER2+	HR-/ HER2?	HR?/ HER2?	Triple-
Outpatient	n	744	146	403	3	38	1	82	71
	%	72.2	19.6	54.2	0.4	5.1	0.1	11.0	9.5
Outpatient and inpatient	n	239	42	138	1	11	0	16	31
	%	23.2	17.6	57.7	0.4	4.6	.	6.7	13.0
Inpatient	n	35	7	17	0	2	0	3	6
	%	3.4	20.0	48.6	.	5.7	.	8.6	17.1
No data on type of care	n	13	0	5	0	0	0	8	0
	%	1.3	.	38.5	.	.	.	61.5	.
Start with MT	n	202	33	92	0	13	1	46	17
	%	19.6	16.3	45.5	.	6.4	0.5	22.8	8.4
Start with COM	n	816	161	470	4	38	0	52	91
	%	79.1	19.7	57.6	0.5	4.7	.	6.4	11.2
No data on start of therapy	n	13	1	1	0	0	0	11	0
	%	1.3	7.7	7.7	.	.	.	84.6	.

Outpatient and inpatient treatments and start of COM or MT treatments in the hospital Clinic Arlesheim by hormone and Her2 status. Legend: MT = mistletoe therapy, COM = chemotherapy and/or hormone therapy and/or surgery and/or radiotherapy, HR = estrogen and/or progesterone receptor, HER = Her2 receptor, Triple-=estrogen, progesterone and Her2 receptor negative, Start with MT=patients started with MT with or without a combination of any type of COM, Start with COM = patients started with any type of COM and complemented or continued with MT later in the course of disease, see Table 3.

ISSN: 2662-7671